Search results
Showing 8806 to 8820 of 8902 results
Adapted shoes recommended for people with severe osteoarthritis
People with osteoarthritis who are eligible for knee surgery could be offered specially adapted shoes to help with their painful and stiff knees following a draft recommendation by NICE.
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer
New life-extending treatment for rare forms of advanced gastroesophageal cancer
Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of gastroesophageal cancer after NICE published final draft guidance today (24 November 2022).
Starting with the end in mind - the Innovative Licensing and Access Pathway
The Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS, bringing significant benefits to patients.
Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE
Improved deal signals NICE recommendation of sickle cell treatment voxelotor.
NICE’s latest quality standard published today (16 March 2022) helps improve the diagnosis, assessment, and prevention of fetal alcohol spectrum disorder (FASD).
Testing could help prevent further strokes in people with gene variant
People who have had an ischaemic stroke or transient ischaemic attack should have a genetic test to find out whether they can be treated with a drug which reduces the risk of further strokes
£1.8m funding awarded to explore guidance on regulating digital mental health tools
NICE and the MHRA have been awarded £1.8m funding by Wellcome over three years to explore and produce guidance on regulating digital mental health tools.
NICE recommends a weekly injection for treating growth failure in children
This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
NICE collaboration on streamlined licensing and patient access process for new medicines
Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.